IGNE IGENE Biotechnology Inc (CE)

 CUSIP No. 451695100
 ---------------------

1. NAME OF REPORTING PERSONS
 I.R.S. IDENTIFICATION NO. OF ABOVE PERSONS (ENTITIES ONLY)

 Sheila Baird

2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*
 (a) [_]
 (b) [X]

3. SEC USE ONLY



4. CITIZENSHIP OR PLACE OF ORGANIZATION

 U.S.A.

NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH

5. SOLE VOTING POWER

 112,716,256

6. SHARED VOTING POWER

 0

7. SOLE DISPOSITIVE POWER

 112,716,256

8. SHARED DISPOSITIVE POWER

 0

9. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

 112,716,256

10. CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES*

 [_]

11. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

 7.4%

12. TYPE OF REPORTING PERSON*

 IN

CUSIP No. 451695100
 ---------------------

Item 1(a). Name of Issuer:

 Igene Biotechnology, Inc.
 -------------------------------------------------------------------


Item 1(b). Address of Issuer's Principal Executive Offices:

 9110 Red Branch Road
 Columbia, Maryland 21045
 -------------------------------------------------------------------


Item 2(a)-(c). Name, Principal Business Address and Citizenship of Persons
 Filing:

 Sheila Baird - United States
 100 Park Avenue
 New York, NY 10017
 U.S.A.


Item 2(d). Title of Class of Securities:

 Common Stock, $0.01 par value
 -------------------------------------------------------------------


Item 2(e). CUSIP Number:

 451695100
 -------------------------------------------------------------------


Item 3. If This statement is filed pursuant to Rule 13d-1(b), or 13d-2(b)
 or (c), check whether certain of the persons filing are a:

 (a) [_] Broker or dealer registered under Section 15 of the Exchange Act.

 (b) [_] Bank as defined in Section 3(a)(6) of the Exchange Act.

 (c) [_] Insurance company as defined in Section 3(a)(19) of the Exchange
 Act.

 (d) [_] Investment company registered under Section 8 of the Investment
 Company Act.

 (e) [_] An investment adviser in accordance with Rule 13d-1(b)(1)(ii)(E);

 (f) [_] An employee benefit plan or endowment fund in accordance with
 Rule 13d-1(b)(1)(ii)(F);

 (g) [_] A parent holding company or control person in accordance with
 Rule 13d-1(b)(1)(ii)(G);

 (h) [_] A savings association as defined in Section 3(b) of the Federal
 Deposit Insurance Act;

 (i) [_] A church plan that is excluded from the definition of an
 investment company under Section 3(c)(14) of the Investment
 Company Act;

 (j) [_] Group, in accordance with Rule 13d-1(b)(1)(ii)(J).

Item 4. Ownership.

 Provide the following information regarding the aggregate number and
percentage of the class of securities of the issuer identified in Item 1.

 (a) Amount beneficially owned:

 112,716,256 shares
-------------------------------------------------------------------

 (b) Percent of class:

 7.4%
-------------------------------------------------------------------

 (c) Number of shares as to which Sheila Baird has:

 (i) Sole power to vote or to direct the vote
 112,716,256
 ______________________,


 (ii) Shared power to vote or to direct the vote
 0
 _____________________,


 (iii) Sole power to dispose or to direct the
 disposition of 112,716,256
 _____________________,

 (iv) Shared power to dispose or to direct the
 disposition of 0
 _____________________.

Item 5. Ownership of Five Percent or Less of a Class.

 If this statement is being filed to report the fact that as of the date
hereof certain the reporting persons have ceased to be the beneficial owner of
more than five percent of the class of securities check the following [ ].

N/A
-------------------------------------------------------------------


Item 6. Ownership of More Than Five Percent on Behalf of Another Person.

 If any other person is known to have the right to receive or the power to
direct the receipt of dividends from, or the proceeds from the sale of, such
securities, a statement to that effect should be included in response to this
item and, if such interest relates to more than five percent of the class, such
person should be identified. A listing of the shareholders of an investment
company registered under the Investment Company Act of 1940 or the beneficiaries
of employee benefit plan, pension fund or endowment fund is not required.

N/A
-------------------------------------------------------------------


Item 7. Identification and Classification of the Subsidiary Which Acquired the
 Security Being Reported on by the Parent Holding Company or Control
 Person.

 If a parent holding company or Control person has filed this schedule,
pursuant to Rule 13d-1(b)(1)(ii)(G), so indicate under Item 3(g) and attach an
exhibit stating the identity and the Item 3 classification of the relevant
subsidiary. If a parent holding company or control person has filed this
schedule pursuant to Rule 13d-1(c) or Rule 13d-1(d), attach an exhibit stating
the identification of the relevant subsidiary.

N/A
-------------------------------------------------------------------


Item 8. Identification and Classification of Members of the Group.

 If a group has filed this schedule pursuant to s.240.13d-1(b)(1)(ii)(J), so
indicate under Item 3(j) and attach an exhibit stating the identity and Item 3
classification of each member of the group. If a group has filed this schedule
pursuant to s.240.13d-1(c) or s.240.13d-1(d), attach an exhibit stating the
identity of each member of the group.

N/A
-------------------------------------------------------------------


Item 9. Notice of Dissolution of Group.

 Notice of dissolution of a group may be furnished as an exhibit stating the
date of the dissolution and that all further filings with respect to
transactions in the security reported on will be filed, if required, by members
of the group, in their individual capacity. See Item 5.

N/A
-------------------------------------------------------------------


Item 10. Certifications.

 By signing below I certify that, to the best of my knowledge and belief,
the securities referred to above were not acquired and are not held for the
purpose of or with the effect of changing or influencing the control of the
issuer of the securities and were not acquired and are not held in connection
with or as a participant in any transaction having that purpose or effect.